MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical...
39 insider purchases on record · latest filing 2020-03-16.
Insiders have also filed 11 sale transactions at MNOV.